Fig. 6: SSO treatment attenuates insulin receptor signaling and reduces vessel formation in SCID mice. | npj Precision Oncology

Fig. 6: SSO treatment attenuates insulin receptor signaling and reduces vessel formation in SCID mice.

From: Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma

Fig. 6

A Mice were injected with 106 Rh30 cells either transfected with NS or SSO55. IGF1-R antibody was administered on days 1 and 3 post-injection. The matrigel plugs were extracted after 7 days for CD34 (endothelial cell marker) staining. The plugs were formalin-fixed and paraffin-embedded, and slides were stained for CD34. Quantification of the CD34 staining from NS and SSO55-treated grafts was done in a blinded manner, n = 10 mice in each condition. The representative IHC pictures for CD34 staining are depicted. The RT-PCR shows the splicing changes in the injected cells in the presence of SSO55. B Model depicting how insulin and IGF-2 bind to IR-A in tumor cells leading to proliferative signaling while in the presence of an IGF-1R antibody and an SSO that shifts the splicing to IR-B, the proliferative signaling (AKT) can be mitigated. Results are shown as the standard error of the mean (±SEM).

Back to article page